Devices descending from K161227
5 later devices reach VITEK 2 AST-GN Cefepime (<=0.12->=32 ug/mL) through their predicates, nearest generation first.
| Generation | Number | Device | Applicant | Decided | Own descendants | Recalls |
|---|---|---|---|---|---|---|
| +1 | K172731 | VITEK 2 AST-GN Amikacin (<=1 ->=64 ug/mL) | bioMerieux, Inc. | 2017 | 3 | — |
| +1 | K163006 | VITEK 2 AST-GN Tigecycline (<0.5->8 ug/mL) | bioMerieux, Inc. | 2017 | 0 | — |
| +2 | K183415 | VITEK 2 AST-Gram Negative Imipenem (</=0.25->= 16 ug/mL) | bioMerieux, Inc. | 2019 | 2 | 1 |
| +3 | K193572 | VITEK 2 AST-Gram Negative Imipenem/Relebactam (<=0.25/4 - >=16/4 µg/mL) | bioMerieux, Inc. | 2020 | 1 | — |
| +4 | K211136 | VITEK 2 AST-Gram Negative Imipenem/Relebactam (<0.25/4 - >16/4 ug/ML) | bioMerieux, Inc. | 2021 | 0 | 1 |